Abstract

Aims Since 2002, there have been five major outcome trials of statins reporting findings from more than 47 000 subjects. As individual trial results differed, we performed a meta‐analysis to ascertain the effectiveness and safety of statins overall and in subgroups. The aim of the study was to estimate the effect of statins on major coronary events and strokes, all‐cause mortality and noncardiovascular mortality, and in different subgroups. Methods PubMed was searched for trials published in English. Randomized placebo‐controlled statin trials with an average follow up of at least 3 years and at least 100 major coronary events were included. For each trial, the statin used, number and type of subjects, proportion of women, mean age and follow up, baseline and change in lipid profile, cardiovascular and non‐cardiovascular outcomes were recorded. Results Ten trials involving 79 494 subjects were included in the meta‐analysis. Due to heterogeneity, ALLHAT‐LLT was excluded from some analyses. Statin therapy reduced major coronary events by 27% (95%CI 23, 30%), stroke by 18% (95%CI 10, 25%) and all‐cause mortality by 15% (95%CI 8, 21%). There was a 4% (95%CI −10, 3%) nonsignificant reduction in noncardiovascular mortality. The reduction in major coronary events is independent of gender and presence of hypertension or diabetes. The risk reduction was greater in smokers ( P < 0.05). Coronary events were reduced by 23% (95%CI 18, 29%) in pravastatin trials and 29% (95%CI 25, 33%) in five trials using other statins. Pravastatin reduced strokes by 12% (95%CI 1, 21%) whilst other statins reduced strokes by 24% (95%CI 16, 32%) ( P = 0.04). Conclusions Statins reduce coronary events, strokes and all‐cause mortality without increasing noncoronary mortality. The benefits accrue in men and women, hypertensives and normotensives, diabetics and nondiabetics, and particularly in smokers. Pravastatin appears to have less impact on strokes.

Keywords

MedicinePravastatinInternal medicineStatinPlaceboRandomized controlled trialMeta-analysisRosuvastatinStroke (engine)Cholesterol

MeSH Terms

Coronary DiseaseHumansHydroxymethylglutaryl-CoA Reductase InhibitorsPravastatinRandomized Controlled Trials as TopicSex FactorsSmokingStroke

Affiliated Institutions

Related Publications

Risk‐based selection from the general population in a screening trial: Selection criteria, recruitment and power for the Dutch‐Belgian randomised lung cancer multi‐slice CT screening trial (NELSON)

Carola A. van Iersel , Harry J. de Koning , Gerrit Draisma +7 more

Abstract A method to obtain the optimal selection criteria, taking into account available resources and capacity and the impact on power, is presented for the Dutch‐Belgian rand...

2006 International Journal of Cancer 484 citations

Publication Info

Year
2004
Type
review
Volume
57
Issue
5
Pages
640-651
Citations
298
Access
Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

298
OpenAlex
8
Influential
221
CrossRef

Cite This

Bernard M.Y. Cheung, I Lauder, Chu‐Pak Lau et al. (2004). Meta‐analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. British Journal of Clinical Pharmacology , 57 (5) , 640-651. https://doi.org/10.1111/j.1365-2125.2003.02060.x

Identifiers

DOI
10.1111/j.1365-2125.2003.02060.x
PMID
15089818
PMCID
PMC1884492

Data Quality

Data completeness: 86%